[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abortion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abortion":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,83,105,127,157,182,211,235],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100630405","phase-2-paracervical-block-with-combined-ketorolac-and-lidocaine-for-osmotic-dilator-placement-100630405",false,"NCT07487246","Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement","Effects of Paracervical Block With Combined Ketorolac and Lidocaine on Perceived Pain in Osmotic Dilator Placement for Abortion, a Randomized Controlled Trial","PCB-KinD","Inclusion criteria:\n\nAge \\>\u002F= 18 years English or Spanish speaking Ability and willingness to sign the informed consent Ability and willingness to comply with the terms of the study including possessing active cell phone with text messaging capabilities Voluntary request for pregnancy termination Ultrasound-confirmed intrauterine pregnancy with an estimated gestational age of 16+0-23+6 weeks gestational age Require osmotic dilator placement one day prior to procedural abortion according to institutional protocol Seeking outpatient abortion services at Rush University Medical Center\n\nExclusion criteria:\n\nHave taken NSAIDs less than 6 hours prior to their clinic visit Contraindications to lidocaine such as allergy to lidocaine, cardiac arrhythmia or heart block, and porphyria Allergic reaction or sensitivity to NSAIDs History of peptic ulcer or gastrointestinal bleed, history of gastric bypass (RYGB) or recent history in last 6 months of gastric sleeve; history of inflammatory bowel disease (Ulcerative colitis, Crohn's disease) Uncontrolled hypertension, heart failure, ischemic heart disease, peripheral arterial disease, cerebrovascular disease Acute renal failure or chronic renal disease Chronic liver disease History of bleeding diathesis Untreated acute cervicitis or pelvic inflammatory disease Require or request PO benzodiazepine or IV sedation for placement of osmotic dilators Require more than 1 day of osmotic dilators Chronic or current narcotic use Current recreational drug use (excluding cannabis) Require transabdominal\u002Ftransvaginal injection for induced fetal demise prior to abortion","FEMALE","18 Years",{"count":20,"type":21},76,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to improve pain management for participantswho need osmotic dilators for cervical preparation the day before their second trimester abortion procedure.",[27,28,29,30],"Pain Management","Abortion","Second Trimester Abortion","Dilation and Evacuation",[32,33,34,35],"randomized controlled trial","osmotic dilators","ketorolac","paracervical block","NOT_YET_RECRUITING","2026-06-15",{"date":39,"type":40},"2026-06-17","ACTUAL",{"date":42,"type":21},"2026-06-29",{"date":44,"type":21},"2027-04-30",{"name":46,"class":47},"Rush University Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100579121","phase-4-tranexamic-acid-for-second-trimester-dilation-and-evacuation-and-bleeding-outcomes-100579121","NCT06820177","Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes","Prophylactic Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Able to understand and sign informed consent\n* Speaks English or Spanish language,\n* Requesting pregnancy termination or procedural management of fetal demise - Intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation\n\nExclusion Criteria:\n\n* History of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism)\n* History of coagulopathy\n* Anticoagulant use in the preceding five days\n* Severe renal impairment\n* Chorioamnionitis or sepsis\n* Suspected placenta accreta spectrum\n* Prophylactic uterotonics other than oxytocin given (or planned to be given) at the start of the D\\&E\n* Known allergic reaction or hypersensitivity to TXA",true,{"count":58,"type":21},276,[60],"PHASE4","Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth. Some guidelines are recommending the use of TXA for both the prevention and management of bleeding for abortion care. However, there are currently no published studies assessing the association between TXA and bleeding outcomes for abortion procedures. This study will involve a randomized, placebo-controlled trial of pregnant patients aged 18 and older desiring dilation and evacuation (D\\&E) for abortion or fetal demise at 18-24 weeks gestation. The primary aim is to determine whether prophylactic TXA has an effect on the need for additional interventions to control bleeding at the time of D\\&E. The secondary aim is to determine whether prophylactic TXA has an effect on the mean quantitative procedural blood loss.",[28,30,63,64,65],"Hemorrhage","Prophylactic Tranexamic Acid Use","Blood Loss",[67,68,69,70,71,72],"abortion","dilation and evacuation","TXA","hemorrhage","Tranexamic acid","D&E","RECRUITING","2026-06-12",{"date":37,"type":40},{"date":77,"type":40},"2025-04-22",{"date":79,"type":21},"2027-05",{"name":81,"class":47},"University of California, San Diego",3,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100641882","ps-ivg--psychosocial-determinants-of-late-term-abortions-14-16-weeks-gestation-at-avignon-hospital-100641882","NCT07650071","PS IVG : Psychosocial Determinants of Late-term Abortions (14-16 Weeks' Gestation) at Avignon Hospital","PS IVG","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Pregnancy ≥ 14 weeks' gestation\n* Patient attending Avignon Hospital for a surgical abortion\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Medical abortion (non-surgical means of abortion)\n* Ectopic pregnancy\n* Inability to complete the questionnaire\n* Patients under legal protection measures (guardianship, curatorship, or court-ordered protection)",{"count":91,"type":21},30,[93],"NA","Abortion is a fundamental right for women in France, where the legal time limit was extended from 14 to 16 weeks' gestation. This extension allows women, whose psychosocial determinants are poorly known, and who face various obstacles (personal, administrative, medical, or other), to access abortion. However, it may also expose them to psychological troubles and difficulties in accessing healthcare. This study aims to identify the psychosocial determinants and disruptions in the primary care pathway associated with late abortions (≥14 weeks' gestation \\[WG\\]) in order to propose preventive actions, particularly regarding contraception, screening, and referral, directly applicable in general practice.",[96,28],"Psychosocial Health","2026-06-10",{"date":99,"type":40},"2026-06-16",{"date":37,"type":21},{"date":102,"type":21},"2027-09-15",{"name":104,"class":47},"Centre Hospitalier Henri Duffaut - Avignon",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100634672","phase-4-diphenhydramine-as-an-adjunct-to-moderate-sedation-for-procedural-first-trimester-abortions-100634672","NCT07542730","Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions","Inclusion Criteria:\n\n* Adults age 18 years and older\n* Desire procedural abortion with moderate sedation\n* Gestational age less than or equal to 13 weeks\n* Intrauterine pregnancy or pregnancy of unknown location\n* Body mass index less than or equal to 40\n\nExclusion Criteria:\n\n* Desire medical abortion or desire to continue pregnancy\n* Gestational age greater than 13 weeks\n* Body mass index greater than 40\n* Age younger than 18 years\n* Confirmed ectopic pregnancy\n* Medical condition that is a contraindication to moderate sedation as determined by the treating clinician",{"count":112,"type":21},98,[60],"This single center, double blind, randomized controlled trial will evaluate whether adding intravenous diphenhydramine to a standard moderate sedation regimen improves pain control during first trimester procedural abortion. Participants undergoing uterine aspiration at less than 13 weeks gestation will be randomized 1 to 1 to receive standard moderate sedation with midazolam and fentanyl plus either diphenhydramine 50 mg intravenously or matching placebo. The primary outcome is participant reported pain during uterine aspiration measured by a 100 mm Visual Analog Scale.",[116,28,117],"Pain","Anxiety","2026-04-19",{"date":120,"type":40},"2026-04-21",{"date":122,"type":21},"2026-05",{"date":124,"type":21},"2027-02",{"name":126,"class":47},"University of Rochester",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":48},"100634300","phase-2-perioperative-dexmedetomidine-to-reduce-post-procedure-grief-following-second-trimester-dilation-and-evacuation-100634300","NCT07537894","Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation","Inclusion Criteria:\n\n* English- or Spanish-fluency\n* 16-26 weeks gestation\n* D\\&E in the operating room\n\nExclusion Criteria:\n\n* Unscheduled or emergent procedure\n* Contraindication to dexmedetomidine per package insert\n* Judgement of clinical anesthesiologist providing care",{"count":134,"type":21},100,[24,136],"PHASE3","People seeking second-trimester dilation and evacuation (D\\&E) procedures are often facing profoundly challenging circumstances, including desired pregnancies complicated by fetal anomalies or demise, serious maternal health conditions, or changes in financial or relationship status. Although abortion regret is uncommon, the emotional burden surrounding these experiences is substantial: many patients experience significant grief and post-traumatic stress symptoms in the weeks to months following care. Perioperative interventions that decrease the body's stress response offer a promising opportunity to reduce downstream psychologic morbidity. Dexmedetomidine has been shown to reduce PTSD symptoms in other high-stress medical and surgical settings. The investigators are undertaking a randomized trial to evaluate whether perioperative administration of dexmedetomidine during second-trimester D\\&E can reduce the frequency and severity of post-procedural grief, directly addressing an unmet need in patient-centered, trauma-informed abortion care.",[28,139,140,141],"Stillbirth","PTSD (Childbirth-Related)","Grief (Traumatic Grief and Existential Grief)",[67,143,144,145,146,147],"dexmedetomidine","fetal demise","stillbirth","grief","PTSD","2026-04-10",{"date":150,"type":40},"2026-04-17",{"date":152,"type":21},"2026-07",{"date":154,"type":21},"2028-07",{"name":156,"class":47},"Stanford University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":48},"100630783","phase-2-efficacy-of-cabergoline-in-inhibiting-lactation-and-alleviating-breast-symptoms-100630783","NCT07492160","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant people aged 18 years or older\n* Gestational age between 12 and 18 weeks\n* Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center\n* Able to provide informed consent\n* Willing and able to complete study surveys\n\nExclusion Criteria:\n\n* Prior mastectomy\n* Currently breastfeeding\n* Current use of a dopamine agonist or dopamine antagonist medication\n* Known contraindication to Cabergoline according to the medication prescribing information",{"count":165,"type":21},348,[24],"The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are:\n\nDoes cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss?\n\nDoes cabergoline reduce the severity of breast symptoms and associated bother compared with placebo?\n\nResearchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss.\n\nParticipants will:\n\nComplete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure\n\nReceive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure\n\nComplete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother\n\nA subset of participants will provide blood samples at selected time points to measure serum prolactin levels",[169,28],"Pregnancy",[171,172],"cabergoline","pregnancy","2026-03-19",{"date":175,"type":40},"2026-03-25",{"date":177,"type":40},"2026-03-16",{"date":179,"type":21},"2028-04",{"name":181,"class":47},"Maimonides Medical Center",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":199,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":48},"100612953","effect-of-an-educational-session-for-abortive-women-on-maternity-nurses-practices-100612953","NCT07260279","Effect of an Educational Session for Abortive Women on Maternity Nurses' Practices","Effect of Educational Sessions for Abortive Care on Maternity Nurses' Performance","EESAW-MNP","Inclusion Criteria:\n\nRegistered maternity nurses working in obstetrics or gynecology departments.\n\nHaving at least one year of clinical experience in maternity or reproductive health units.\n\nWilling to participate and provide informed consent.\n\nAble to read and understand the educational materials provided.\n\nPresent at the workplace during the study and follow-up periods.\n\nNot previously involved in similar abortion care training programs.\n\nExclusion Criteria:\n\nNurses on maternity or annual leave during the study period.\n\nAdministrative or non-clinical nursing staff.\n\nNurses with less than one year of professional experience.\n\nRefusal to participate or withdrawal at any stage of the study.\n\nAttendance of any concurrent external training on abortion or reproductive health during the study.\n\nIncomplete participation in the educational intervention sessions.","20 Years","60 Years",{"count":193,"type":21},60,[93],"The goal of this study is to evaluate the effect of structured educational sessions for abortive women on the practices of maternity nurses.\n\nThe study aims to enhance nurses' clinical skills and patient care related to abortion management.\n\nParticipants will:\n\nAttend educational sessions designed to improve nursing practices\n\nParticipate in activities and discussions led by experienced instructors\n\nBe observed before and after the sessions to assess changes in clinical practices\n\nThe study will compare nursing practices before and after the intervention to determine the overall impact of the educational sessions on professional performance and patient care quality.",[28,197,198],"Practice","Maternity",[28,200,201],"Maternity nurses","Practices","2026-02-28",{"date":204,"type":40},"2026-03-03",{"date":206,"type":21},"2026-02-01",{"date":208,"type":21},"2026-12",{"name":210,"class":47},"Mansoura University",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":220,"phases":4,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":234},"100376615","effects-of-prior-induced-termination-of-pregnancy-on-complications-and-pregnancy-outcomes-100376615","NCT04183829","Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.","Inclusion Criteria:\n\n* women have induced abortion in early pregnancy (\\\u003C12 weeks of gestation).\n* permanent population and no tendency to move.\n* normal language expression and understanding ability, able to understand research content.\n* be able and willing to provide written informed consent and effective contact information, and be willing to cooperate with follow-up investigations.\n\nExclusion Criteria:\n\n* above the age of 40\n* with history of adverse pregnancy and childbirth","40 Years",{"count":219,"type":21},20000,"OBSERVATIONAL","A prospective multicenter cohort study to evaluate effects of prior induced termination of pregnancy on complications and pregnancy outcomes.",[223,28],"Reproductive Health","2025-09-05",{"date":226,"type":40},"2025-09-12",{"date":228,"type":40},"2019-06-01",{"date":230,"type":21},"2028-06",{"name":232,"class":233},"National Research Institute for Family Planning, China","OTHER_GOV",12,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":242,"enrollmentInfo":243,"targetDuration":245,"studyType":220,"phases":4,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":48},"100573157","comparative-psychiatric-problems-between-first-and-second-trimester-miscarriage-100573157","NCT06742632","Comparative Psychiatric Problems Between First and Second Trimester Miscarriage","Comparative Study in Psychiatric Problems Among Mothers With Miscarriage in First and Second Trimester","Inclusion Criteria:\n\n* all miscarrying women less than or equal to 26 weeks gestation\n\nExclusion Criteria:\n\n* ectopic pregnancy and vesicular mole","45 Years",{"count":244,"type":21},155,"1 Month","Description of the psychiatric impact of miscarriage on women.",[28],[67],"2024-12-18",{"date":251,"type":40},"2024-12-19",{"date":253,"type":21},"2024-12-15",{"date":255,"type":21},"2025-02-01",{"name":257,"class":47},"Assiut University"]